clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.
Company profile
Ticker
CLNN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Chelsea Worldwide Inc.
SEC CIK
Corporate docs
Subsidiaries
Clene Nanomedicine, Inc. • Clene Australia Pty Ltd • dOrbital, Inc. • Clene Netherlands B.V. ...
CLNN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
8-K
Regulation FD Disclosure
16 Apr 24
8-K
Entry into a Material Definitive Agreement
9 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
8-K
Clene Reports Full Year 2023 Financial Results
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Regulation FD Disclosure
29 Feb 24
8-K
Regulation FD Disclosure
22 Feb 24
Latest ownership filings
4
Change in insider ownership
16 Apr 24
4
Matthew Kiernan
12 Mar 24
4
DAVID J MATLIN
12 Mar 24
4
Vallerie McLaughlin
12 Mar 24
4
Alison Mosca
12 Mar 24
4
Arjun JJ Desai
12 Mar 24
4
Shalom Jacobovitz
12 Mar 24
4
Jonathon Gay
12 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Mosca Alison
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 42.17 mm | 42.17 mm | 42.17 mm | 42.17 mm | 42.17 mm | 42.17 mm |
Cash burn (monthly) | 2.38 mm | (no burn) | 3.18 mm | 4.84 mm | 2.25 mm | 2.56 mm |
Cash used (since last report) | 15.74 mm | n/a | 21.06 mm | 32.07 mm | 14.92 mm | 16.95 mm |
Cash remaining | 26.43 mm | n/a | 21.11 mm | 10.10 mm | 27.25 mm | 25.22 mm |
Runway (months of cash) | 11.1 | n/a | 6.6 | 2.1 | 12.1 | 9.9 |
Institutional ownership, Q3 2023
33.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 5 |
Closed positions | 8 |
Increased positions | 15 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 12.13 bn |
Total shares | 42.37 mm |
Total puts | 326.00 k |
Total calls | 132.60 k |
Total put/call ratio | 2.5 |
Largest owners | Shares | Value |
---|---|---|
Vivo Opportunity Fund | 17.74 mm | $16.32 mm |
AIGH Capital Management | 5.80 mm | $2.88 bn |
AWM Investment | 5.00 mm | $2.48 bn |
Vivo Capital | 2.65 mm | $1.40 bn |
Vanguard | 2.45 mm | $1.21 bn |
Alyeska Investment | 1.86 mm | $921.55 mm |
Worth Venture Partners | 1.40 mm | $696.38 mm |
Scoggin Management | 750.00 k | $371.93 mm |
Geode Capital Management | 611.85 k | $303.54 mm |
Lunt Capital Management | 512.86 k | $254.33 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | General Resonance | Common Stock | Sell | Dispose S | No | No | 0.3831 | 7,500 | 2.87 k | 15,428,212 |
9 Apr 24 | General Resonance | Common Stock | Sell | Dispose S | No | No | 0.3871 | 7,500 | 2.90 k | 15,435,712 |
9 Apr 24 | General Resonance | Common Stock | Sell | Dispose S | No | No | 0.3864 | 7,500 | 2.90 k | 15,443,212 |
11 Mar 24 | Matthew Kiernan | Stock Options Common Stock | Grant | Acquire A | No | No | 0.44 | 29,481 | 12.97 k | 29,481 |
11 Mar 24 | Matlin David J | Stock Options Common Stock | Grant | Acquire A | No | No | 0.44 | 57,488 | 25.29 k | 57,488 |
11 Mar 24 | Vallerie McLaughlin | Stock Options Common Stock | Grant | Acquire A | No | No | 0.44 | 32,429 | 14.27 k | 32,429 |
11 Mar 24 | Alison Mosca | Stock Options Common Stock | Grant | Acquire A | No | No | 0.44 | 44,959 | 19.78 k | 44,959 |
News
The Analyst Verdict: Clene In The Eyes Of 5 Experts
17 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
17 Apr 24
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
17 Apr 24
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
17 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
16 Apr 24
Press releases
Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
16 Apr 24
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
19 Mar 24
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
13 Mar 24
Clene Inc. announces positive results from CNM-Au8 results from MS trial
5 Feb 24